Fibrosis biomarker assay
US9880177B2 · kind B2 · utility
1Cited by
7References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 1, 2017 |
| Grant date | Jan 30, 2018 |
| Priority date | — |
| Expiry date | Mar 1, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/50
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method of bioassay for the quantification of biomarkers useful in the diagnosis of fibrosis disease and prognosis of its development, including biomarkers indicative of the risk of developing fibrosis after a chronic injury is provided. In particular, according to the present invention, biomarkers relating to degradation fragments of Collagen type I, III, IV, V, and VI, elastin, C-reactive protein, and proteoglycans including Biglycan, Decorin, Versican, and Perlecan are found to be useful.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.